항체약물접합체 시장 : 적응증별, 치료 분야별, 링커별, 페이로드별, 표적 항원별, 주요 지역별 - 산업 동향 및 세계 예측(-2035년)

Antibody Drug Conjugate Market by Target Disease Indication,Therapeutic Area, Linker, Payload, Target Antigens And Key Geographical Regions: Industry Trends and Global Forecasts, Till 2035

US $ 4,799 ￦ 6,630,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,999 ￦ 9,670,000

PDF (One-Location Site License)

PDF 보고서를 동일 사업장의 특정 사업 부문에 속한 모든 분들이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,599 ￦ 14,644,000

PDF (Department License)

PDF 보고서를 부서 단위로 12명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 17,999 ￦ 24,869,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계 항체약물접합체 시장 규모는 2035년까지 예측 기간 동안 9.63%의 CAGR로 확대되어 현재 77억 2,000만 달러에서 2035년까지 233억 달러로 성장할 것으로 예상됩니다.

수년 동안 약동학적 및 약력학적 특성의 개선과 항체 공학 등 다양한 기술 개발로 인해 항체약물접합체가 고형암 및 혈액 악성 종양 치료에서 실행 가능한 치료 수단으로 간주될 수 있는 길이 열렸습니다. 현재까지 280개 이상의 항체약물접합체가 승인되었거나 임상시험 중이고, 250개 이상의 후보물질이 개발 초기 단계에 있습니다. 미국 식품의약국(USFDA)이 승인한 약물의 예로는 진론타, 아카락스, 에이지엑스 등이 있습니다.

항체약물접합체는 부작용을 최소화하면서 종양 집단을 선택적으로 제거할 수 있는 대안으로 떠오르고 있습니다. 현재까지 여러 임상시험에서 항체약물접합체의 치료적 우월성(기존 암 치료 옵션을 능가하는 효과)과 효능이 입증됐습니다. 따라서 다양한 암 질환 환자 수의 증가는 항체약물접합체 시장의 주요 촉진요인 중 하나입니다. 혁신적인 기술 플랫폼의 가용성, 유리한 자금 조달 기회, 유망한 임상시험 결과 등에 힘입어 향후 10년간 여러 제품 후보가 판매 승인을 받을 것으로 예상됨에 따라 항체약물접합체 시장은 장기적으로 성장할 것으로 예상됩니다.

이 보고서는 세계 항체약물접합체 시장을 조사하여 시장 개요와 함께 적응증별, 치료 분야별, 링커별, 페이로드별, 표적 항원별, 지역별 동향, 시장 진입 기업 개요 등을 제공합니다.

목차

제1장 서문

제2장 주요 요약

제3장 소개

제4장 시장 개요

제5장 타겟 경쟁력 분석

제6장 기업과 약제 프로파일

• 분석 개요
• ADC Therapeutics
• Astellas Pharma
• AstraZeneca
• Byondis
• Daiichi Sankyo
• Genentech
• Gilead Sciences
• ImmunoGen
• Pfizer
• RemeGen
• Seagen

제7장 임상시험 분석

제8장 주요 오피니언 리더

제9장 병용요법

제10장 파트너십과 협업

제11장 자금 조달과 투자 분석

제12장 특허 분석

제13장 학술 조성금 분석

제14장 주요 상업화 전략

제15장 프로모션 분석

제16장 성공 프로토콜 분석

제17장 새로운 결합과 링커 기술 플랫폼

제18장 인간에 대한 투여의 비임상 데이터 평가

제19장 원가 분석

제20장 사례 연구 1 : 항체약물접합체 수탁제조

제21장 사례 연구 2 : 항체약물접합체 치료를 위한 동반진단

제22장 SWOT 분석

제23장 시장 예측과 기회 분석

제24장 이그제큐티브 인사이트

• 분석 개요
• Oxford Biotherapeutics
• Angiex
• Syndivia
• BSP Pharmaceuticals
• PolyTherics(an Abzena company)
• CureMeta
• CytomX Therapeutics
• NBE-Therapeutics
• Cerbios-Pharma
• Eisai
• AbTis
• AmbrX
• Synaffix
• Pierre Fabre
• Catalent Pharma Solutions
• Lonza
• Piramal Healthcare
• Ajinomoto Bio-Pharma Services
• Cardiff University
• 기타

제25장 결론

제26장 부록 1 : 표형식 데이터

제27장 부록 2 : 기업·단체 리스트

ksm

영문 목차

영문목차

ANTIBODY DRUG CONJUGATE MARKET: OVERVIEW

As per Roots Analysis, the global antibody drug conjugate market is estimated to grow from USD 7.72 billion in the current year to USD 23.3 billion by 2035, at a CAGR of 9.63% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Target Disease Indication

• Breast Cancer
• B-cell Lymphoma
• Lung Cancer
• Multiple Myeloma
• Acute Lymphoblastic Leukemia
• Gastric Cancer
• Renal Cancer
• Cervical Cancer
• Other Target Disease Indications

Therapeutic Area

• Hematological Cancer
• Solid Tumor

Linker

• Valine-Citrulline
• Succinimidyl-4-(N-Maleimidomethyl) Cyclohexane-1-Carboxylate
• Tetrapeptide-based Linker
• Maleimide, Maleimidocaproyl
• Valine-Alanine
• Hydrazone (4-(4-Acetylphenoxy) Butanoic Acid (AcBut)
• Other Linkers

Payload

• Monomethyl Auristatin E
• DM1
• Duocarmycin
• SN-38 / Irinotecan
• Monomethyl Auristatin F
• SG3199
• Ozogamicin
• DM4
• Other Payloads

Target Antigens

• HER-2 (ERBB2)
• CD79b
• Trop-2
• BCMA (TNFRSF17 / BCM)
• CD19
• CD22
• Tissue Factor
• CD30
• CEACAM5
• Nectin 4
• Others

Key Geographical Regions

• North America
• Europe
• Asia-Pacific

ANTIBODY DRUG CONJUGATE MARKET: GROWTH AND TRENDS

Over the years, various technical developments, such as enhanced pharmacokinetic and pharmacodynamic properties and antibody engineering have paved the way for antibody drug conjugates to be considered as a viable therapeutic modality for the treatment of solid tumors and hematological malignancies. Till date, over 280 antibody drug conjugates have been either approved or being investigated in clinical studies, whereas more than 250 candidates are in the early stages of development. Examples of the USFDA approved drugs include Zynlonta, Akalux, Aidixi.

Antibody drug conjugates have emerged as a potential option to selectively eliminate the tumor population, with minimal side effects. Till date, several clinical trials have shown the therapeutic superiority (over conventional cancer treatment options) and efficacy of antibody-drug conjugates. Therefore, the rising population of various oncological disorders is one of the key drivers for the antibody drug conjugate market. Driven by the availability of innovative technology platforms, lucrative funding opportunities and encouraging clinical trial results, the antibody drug conjugates market is poised to grow in the long-run, as multiple product candidates are expected to receive marketing approval in the coming decade.

ANTIBODY DRUG CONJUGATE MARKET: KEY INSIGHTS

The report delves into the current state of the antibody drug conjugate market and identifies potential growth opportunities within the industry. Some key findings from the report include:

• 1. The landscape of ADCs has steadily evolved over the past decade; more than 530 ADC therapy programs are being evaluated by over 140 drug developers, worldwide.
• 2. Currently, 47% of the ADCs are in discovery / preclinical stages of development; of these, close to 160 ADCs utilize auristatin and maytansinoid payloads.
• 3. In order to gain a competitive edge, ADC developers are actively exploring novel targets for the treatment of a wide array of indications.
• 4. Since 2010, 560+ clinical trials have been registered to evaluate the safety and efficacy of various ADCs; majority of these studies have been conducted across various sites in the US.
• 5. Developers have already evaluated more than 190 ADCs in combination with other therapeutic modalities for the treatment of various oncological disorders.
• 6. The growing interest in this field is evident from the rise in partnership activity over the years; in fact, the maximum partnerships, till date, were inked recently.
• 7. Considering the enormous opportunities associated with ADCs for the treatment of cancer, investors have readily extended funds, worth nearly USD 30 billion, in the last decade.
• 8. Several researchers from renowned universities, currently involved in evaluating efficacy and safety of ADCs, have emerged as prominent KOLs.
• 9. Over the years, the intellectual capital related to the therapeutic applications of ADCs has grown at a commendable pace; more than 3,330 patents have been filed by both industry and non-industry players.
• 10. A number of grants, worth over USD 135 million, have been awarded for research activity related to ADCs; nearly 90% of these grants extend a support period of up to 10 years.
• 11. Stakeholders are exploring diverse commercialization strategies across different stages of a drug's launch cycle; for drugs nearing patent expiry, these developers are expected to adopt lifecycle management strategies.
• 12. Presently, around 35 players, across the globe, claim to have the required capabilities to offer contract manufacturing / conjugation services for ADCs; of these, over 10 players claim to be one-stop-shops.
• 13. With a promising developmental pipeline, the global market is anticipated to witness an annualized growth of nearly 10% over the next decade.

ANTIBODY DRUG CONJUGATE MARKET: KEY SEGMENTS

Breast Cancer is Likely to Dominate the Antibody Drug Conjugate Market During the Forecast Period

Based on the target disease indication, the market is segmented into breast cancer, b-cell lymphoma, lung cancer, multiple myeloma, acute lymphoblastic leukemia, gastric cancer, renal cancer, cervical cancer and other target disease indications. Currently, a number of antibody drug conjugates have been approved for the treatment of breast cancer patients. This segment is expected to capture the largest share as more drug candidates receive approvals in the future.

Currently, Solid Tumor Holds Maximum Share within the Antibody Drug Conjugate Market

Based on the therapeutic area, the market is segmented into hematological cancer and solid tumor. It is worth highlighting that antibody drug conjugate market for solid tumor is likely to grow at a relatively higher CAGR, during the forecast period.

Maleimidocaproyl is the Fastest Growing Segment in the Antibody Conjugate Market During the Forecast Period

Based on the type of linker, the market is segmented into valine-citrulline, succinimidyl-4-(n-maleimidomethyl) cyclohexane-1-carboxylate, tetrapeptide-based linker, maleimidocaproyl, valine-alanine, hydrazone (4-(4-acetylphenoxy) butanoic acid (acbut) and other linkers. It is worth highlighting that the current antibody drug conjugate market is dominated by valine-citrulline linkers.

Monomethyl auristatin E (MMAE) Payload is Likely to Dominate the Antibody Drug Conjugate Market During the Forecast Period

Based on the type of payload, the market is segmented into Monomethyl Auristatin E, DM1, Duocarmycin, SN-38 / Irinotecan, Monomethyl Auristatin F, SG3199, Ozogamicin, DM4 and other Payloads. The current market is expected to be driven by MMAE payload used in antibody drug conjugates, followed by DM1; a similar trend is anticipated in the long term.

Currently, HER-2 (ERBB2) Target Antigen Holds the Maximum Share within the Antibody Drug Conjugate Market

Based on the target antigen, the market is segmented into HER-2 (ERBB2), CD79b, Trop-2, BCMA (TNFRSF17 / BCM), CD19, CD22, tissue factor, CD30, CEACAM5, Nectin 4 and others.

The market is expected to be driven by HER-2 (ERBB2) antigen, CD79b target antigen and TROP-2 antigen in mid-long term. It is worth highlighting that the antibody drug conjugate market for tissue factor is likely to grow at a relatively higher CAGR during the forecast period.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe and Asia-Pacific. Majority share is expected to be captured by drug developers based in North America and Europe. It is worth highlighting that over the years, the market in Asia-Pacific is expected to grow at a higher CAGR.

Example Players in the Antibody Drug Conjugates Market

• ADC Therapeutics
• Astellas Pharma
• AstraZeneca
• Byondis
• Daiichi Sankyo
• Genentech
• Gilead Sciences
• ImmunoGen
• Pfizer
• RemeGen

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

• Founder and Chief Executive Officer, Oxford Biotherapeutics
• Founder and Chief Operating Officer, Angiex
• Co-Founder and Chief Executive Officer, Syndivia
• President and Chief Executive Officer, BSP Pharmaceuticals
• Former Chief Executive Officer, PolyTherics (an Abzena company)
• Founder and Chief Executive Officer, CureMeta
• Chief Business Officer and Head of Strategy, CytomX Therapeutics
• Former Chief Business Officer, NBE-Therapeutics
• Chief Commercial Officer, Cerbios-Pharma
• Senior Vice President and Chief Scientific Officer, Eisai
• Chief Business Officer, AbTis
• Former Vice President and Head of Chemistry, AmbrX
• Vice President, Business Development, Synaffix
• Former Director, Pierre Fabre
• Former Group Product Manager, Catalent Pharma Solutions
• Former Head of Bioconjugates Commercial Development, Lonza
• Former Site Head, Piramal Healthcare
• General Manager, Business Development, CDMO Business, Ajinomoto Bio-Pharma Services
• Professor, Cardiff University

ANTIBODY DRUG CONJUGATE MARKET: RESEARCH COVERAGE

• The report features an in-depth analysis of the antibody drug conjugate market, focusing on key market segments, including target disease indication, therapeutic area, linker, payload, target antigens and key geographical regions.
• A comprehensive evaluation of close to 400 antibody drug conjugates / ADC therapeutics that have been either approved or being evaluated in different stages of development, considering various parameters, such as status of development (Approved, Phase III, Phase II, Phase I and Discovery / Preclinical), target disease indication (breast cancer, lung cancer, gastric cancer, ovarian cancer, non-Hodgkin's lymphoma, hepatic cancer, b-cell lymphoma, acute myeloid leukemia, brain cancer and renal cancer), therapeutic area (solid tumors, hematological cancers, autoimmune disorders / inflammatory disorders and others), line of treatment (1st line, >=1st line, 2nd line, >=2nd line, 3rd line, >=3rd line, <=4th line, Last line and others), dosing frequency (q3 weeks, q2 weeks, q1 weeks, q4 weeks, once and q6 weeks), type of therapy (combination therapy and monotherapy), target antigen (HER-2 (ERBB2), Trop-2, EGFR, FOLR1 (folate receptor alpha), CD30, B7-H3 (CD276), Nectin 4 and c-MET), antibody isotype (IgG1, IgG2 and IgG4), payload / cytotoxin / warhead (monomethyl auristatin E (MMAE), DM4, DM1, SG3199, SN-38 / irinotecan, duocarmycin and monomethyl auristatin F (MMAF)), type of payload (auristatin, Maytansinoid, camptothecin, exatecan derivative topoisomerase I inhibitor, pyrrolobenzodiazepine dimer, topoisomerase I inhibitor (unspecified), DNA topoisomerase I inhibitor, Seco-DUBA, calicheamicin (ozogamicin), glucocorticoid and pyrrolobenzodiazepine (PBD)), linkers (valine-citrulline, peptide linker, tetrapeptide-based linker, N-succinimidyl 4-(2-pyridyldithio) -butanoate (SPDB), valine-alanine, succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate and maleimide linker) and type of linkers (cleavable and non-cleavable). In addition, it includes information on various antibody drug conjugate developers, based on their year of establishment, company size, location of headquarters and most active players (in terms of number of therapies).
• A comprehensive competitive analysis of biological targets, examining factors, such as number of antibody drug conjugates being developed against them, number of unique target disease indications and number of companies developing antibody-drug conjugates for the target. In addition, it includes a six-dimensional spider-web analysis, featuring the most popular biological targets based on a number of relevant parameters, including number of publications, number of grants received to support research on a particular target, number of companies involved in drug development based on a singular target, highest phase of development for the singular target, number of therapies and number of indications.
• In-depth profiles of key industry players in antibody drug conjugate market, focusing on company overviews, financial information (if available), product portfolio, recent developments, and an informed future outlook.
• Detailed profiles of marketed ADC therapeutics, focusing on overview of the therapy, its mechanism of action, target antigen, linker, payload, type of therapy and details related to sales generated (wherever available).
• Examination of completed, ongoing, and planned clinical studies of various drug conjugates based on several parameters, such as trial registration year, trial status, trial phase, enrolled patient population, type of sponsor / collaborator, target population, study design, most active industry players, and non-industry players (in terms of number of trials) and key geographical regions.
• An in-depth examination that emphasizes the key opinion leaders (KOLs) within this field includes an evaluation of various principal investigators overseeing clinical trials associated with antibody drug conjugates, based on several relevant parameters, such as type of KOL, qualification(s), type of organization, affiliated organization, geographical location of KOLs and target disease indications. In addition, the chapter highlights the most prominent KOLs, based on our proprietary and third-party scoring criteria.
• An assessment of various therapeutics that are being evaluated in combination with antibody-drug conjugates. The study also presents the likely evolution of these therapeutics across different indications.
• An analysis of partnerships established in this sector, since 2014, covering product licensing agreements, technology licensing agreements, research and development agreements, clinical trial agreements, mergers / acquisitions, product development agreements, technology utilization agreements, product development and commercialization agreements, manufacturing agreements, technology integration agreements and others), purpose of partnership (research and development, product development and commercialization, product development, clinical evaluation, portfolio enhancement, product development and manufacturing, manufacturing, research and others.
• A detailed evaluation of the investments made in the ADC domain, encompassing seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings based on several parameters, such as number of funding instances, amount invested, type of funding, leading companies and investors, and geographical analysis.
• Detailed analysis of various patents filed / granted related to antibody drug conjugates based on type of patent, patent publication year, patent application year, geographical location, type of players, assigned CPC symbol, type of organization, and leading industry / academic players (in terms of size of intellectual property portfolio). It also includes a patent benchmarking analysis and a detailed valuation analysis.
• A comprehensive evaluation of various grants that have been awarded to research institutes engaged in conducting research related to antibody drug conjugates, since 2016, based on various important parameters, such as year of grant award, amount awarded, funding institute center, support period, type of grant application, purpose of grant award, activity code, study section involved, popular NIH departments (based on number of grants awarded), prominent program officers, leading recipient organizations and key regions.
• A detailed analysis of the commercialization strategies employed by different drug developers for their respective products, prior to launch, during / post launch. It also includes a proprietary framework to outline the essential steps and guidelines that companies can follow while developing their marketing strategies.
• An analysis of the key promotional strategies that have been adopted by the developers of marketed products, namely Adcetris, Besponsa, Enhertu, Kadcyla, Mylotarg, Polivy, and Trodelvy.
• Assessment of the success protocol model for the recently approved ADC therapeutics, based on several relevant parameters, such as dosing frequency, drug efficacy, drug exclusivity, fatality rate, geographical reach, intra-class competition, line of treatment, prevalence, price, type of therapy, and existing competition among developers.
• An overview of various conjugation and linker technologies along with the types that are presently being employed in the designing and development of antibody drug conjugates. In addition, it presents a list of the conjugation and linker technologies that are presently being employed in the designing and development of antibody drug conjugates.
• An overview of research aimed at enhancing the analysis of non-clinical data to support first-in-human (FIH) dose selection for antibody drug conjugates. It also examines the various methods employed to estimate FIH doses. Additionally, it highlights potential FIH starting doses and the estimated dose escalations necessary to achieve the maximum tolerated dose (MTD) in humans.
• A comprehensive discussion on the various factors that are likely to influence the pricing of antibody drug conjugate products. This includes an exploration of different models and approaches that pharmaceutical companies may consider while determining the prices of their lead therapy candidates that are likely to be marketed in the near future.
• A case study on manufacturing of antibody drug conjugates, highlighting the key challenges, and a list of contract service providers that are involved in the ADC market.
• A case study on companies offering companion diagnostics that can potentially be used to make treatment related decisions involving antibody-drug conjugates, providing information on the geographical location of key diagnostic developers, affiliated disease biomarkers, assay techniques involved, target indications, the type of sample required (tumor tissue, blood, bone marrow and others) and the drug candidates for which a particular test was developed.
• A SWOT analysis, focusing on key drivers and challenges that are likely to impact the industry's evolution. Further, it includes a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall industry.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What kind of partnership models are commonly adopted by industry stakeholders?
• What are the factors that are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 10% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1.PREFACE

• 1.1. Antibody Drug Conjugate Market Overview
• 1.2. Key Market Insights
• 1.3. Scope of the Report
• 1.4. Research Methodology
• 1.5. Key Questions Answered
• 1.6. Chapter Outlines

2.EXECUTIVE SUMMARY

3.INTRODUCTION

• 3.1.Chapter Overview
• 3.2.Pillars of Cancer Therapy
• 3.3.Overview of Antibody Drug Conjugates
  • 3.3.1.History of Antibody Drug Conjugates
  • 3.3.2.Difference between Small Molecule Drugs, Monoclonal Antibody Therapies and Antibody Drug Conjugates
  • 3.3.3.Components of Antibody Drug Conjugates
    • 3.3.3.1.Antibody
    • 3.3.3.2.Cytotoxin
    • 3.3.3.3.Linker
  • 3.3.4.Advantages of Antibody Drug Conjugates Therapeutics over Traditional Therapeutics
  • 3.3.5.Pharmacokinetic Properties of Antibody-Drug Conjugates
    • 3.3.5.1. Absorption
    • 3.3.5.2. Distribution
    • 3.3.5.3. Metabolism and Elimination
• 3.4.Concluding Remarks

4. MARKET OVERVIEW

• 4.1.Chapter Overview
• 4.2.Antibody Drug Conjugates: Therapies Pipeline
  • 4.2.1.Analysis by Status of Development
  • 4.2.2.Analysis by Target Disease Indication
  • 4.2.3.Analysis by Therapeutic Area
  • 4.2.4.Analysis by Line of Treatment
  • 4.2.5.Analysis by Dosing Frequency
  • 4.2.6.Analysis by Type of Therapy
  • 4.2.7.Analysis by Target Antigen
  • 4.2.8.Analysis by Antibody Isotype
  • 4.2.9.Analysis by Payload / Cytotoxin / Warhead
  • 4.2.10.Analysis by Type of Payload
  • 4.2.11.Analysis by Linker
  • 4.2.12.Analysis by Type of Linker (Cleavable / Non-Cleavable)
• 4.3.Antibody Drug Conjugate: List of Therapy Developers
  • 4.3.1.Analysis by Year of Establishment
  • 4.3.2.Analysis by Company Size
  • 4.3.3.Analysis by Location of Headquarters
  • 4.3.4.Analysis by Company size and Location of Headquarters
  • 4.3.5.Most Active Players: Analysis by Number of Therapies

5. TARGET COMPETITIVENESS ANALYSIS

• 5.1.Chapter Overview
• 5.2.Key Parameters
• 5.3.Methodology
• 5.4.Target Competitiveness Analysis: Key Targets of Antibody Drug Conjugates
  • 5.4.1.Three-Dimensional Bubble Analysis
    • 5.4.1.1.Targets of Approved / Marketed Drugs
    • 5.4.1.2.Targets of Phase III Drugs
    • 5.4.1.3.Targets of Phase II Drugs
    • 5.4.1.4.Targets of Phase I Drugs
    • 5.4.1.5.Targets of Pre-Clinical Drugs
  • 5.4.2.Six-Dimensional Spider Web Analysis

6.COMPANY AND DRUG PROFILES

• 6.1.Chapter Overview
• 6.2.ADC Therapeutics
  • 6.2.1.Company Overview
  • 6.2.2.Financial Information
  • 6.2.3.Pipeline Overview
    • 6.2.3.1.Zynlonta
  • 6.2.4.Recent Developments and Future Outlook
• 6.3.Astellas Pharma
  • 6.3.1.Company Overview
  • 6.3.2.Financial Information
  • 6.3.3.Pipeline Overview
    • 6.3.3.1.Padcev
  • 6.3.4.Recent Developments and Future Outlook
• 6.4.AstraZeneca
  • 6.4.1.Company Overview
  • 6.4.2.Financial Information
  • 6.4.3.Pipeline Overview
    • 6.4.3.1.Enhertu
  • 6.4.4.Recent Developments and Future Outlook
• 6.5.Byondis
  • 6.5.1.Company Overview
  • 6.5.2.Financial Information
    • 6.5.2.1.Pipeline Overview
  • 6.5.3.Trastuzumab duocarmazine
  • 6.5.4.Recent Developments and Future Outlook
• 6.6.Daiichi Sankyo
  • 6.6.1.Company Overview
  • 6.6.2.Financial Information
  • 6.6.3.Pipeline Overview
    • 6.6.3.1.Enhertu
  • 6.6.4.Recent Developments and Future Outlook
• 6.7.Genentech (Subsidiary of Roche)
  • 6.7.1.Company Overview
  • 6.7.2.Financial Information
  • 6.7.3.Pipeline Overview
    • 6.7.3.1.Kadcyla
    • 6.7.3.2.Polivy
  • 6.7.4.Recent Developments and Future Outlook
• 6.8.Gilead Sciences
  • 6.8.1.Company Overview
  • 6.8.2.Financial Information
  • 6.8.3.Pipeline Overview
    • 6.8.3.1.Trodelvy
  • 6.8.4.Recent Developments and Future Outlook
• 6.9.ImmunoGen
  • 6.9.1.Company Overview
  • 6.9.2.Financial Information
  • 6.9.3.Pipeline Overview
    • 6.9.3.1.Elahere
  • 6.9.4.Recent Developments and Future Outlook
• 6.10.Pfizer
  • 6.10.1.Company Overview
  • 6.10.2.Financial Information
  • 6.10.3.Pipeline Overview
    • 6.10.3.1.Mylotarg
    • 6.10.3.2.Besponsa
  • 6.10.4.Recent Developments and Future Outlook
• 6.11.RemeGen
  • 6.11.1.Company Overview
  • 6.11.2.Financial Information
  • 6.11.3.Pipeline Overview
    • 6.11.3.1.Disitamab vedotin
  • 6.11.4.Recent Developments and Future Outlook
• 6.12.Seagen
  • 6.12.1.Company Overview
  • 6.12.2.Financial Information
  • 6.12.3.Pipeline Overview
    • 6.12.3.1.Adcetris
    • 6.12.3.2.Padcev
    • 6.12.3.3.Tivdak
  • 6.12.4.Recent Developments and Future Outlook

7.CLINICAL TRIAL ANALYSIS

• 7.1.Chapter Overview
• 7.2.Scope and Methodology
• 7.3.Antibody Drug Conjugates: Clinical Trial Analysis
  • 7.3.1.Analysis by Trial Registration Year
  • 7.3.2.Analysis by Trial Status
  • 7.3.3.Analysis by Trial Status and Patients Enrolled
  • 7.3.4.Analysis by Trial Registration Year and Trial Status
  • 7.3.5.Analysis by Trial Registration Year and Patients Enrolled
  • 7.3.6.Analysis by Trial Phase
  • 7.3.7.Analysis by Trial Phase and Patients Enrolled
  • 7.3.8.Analysis by Type of Sponsor / Collaborator
  • 7.3.9.Analysis by Target Population
  • 7.3.10.Analysis by Study Design
  • 7.3.11.Most Active Industry Players: Analysis by Number of Trials
  • 7.3.12.Most Active Non-Industry Players: Analysis by Number of Trials
  • 7.3.13.Analysis of Clinical Trials by Geography
  • 7.3.14.Analysis of Patients Enrolled by Geography

8. KEY OPINION LEADERS

• 8.1.Chapter Overview
• 8.2.Assumption and Key Parameters
• 8.3.Methodology
• 8.4.Antibody Drug Conjugates: Key Opinion Leaders
  • 8.4.1.Analysis by Type of KOLs
  • 8.4.2.Analysis by Qualification
  • 8.4.3.Analysis by Affiliated Organization
  • 8.4.4.Analysis by Type of Organization
  • 8.4.5.Analysis by Geographical Location of KOLs
  • 8.4.6.Most Prominent KOLs: Analysis by KOLs Activeness, Expertise and Strength
  • 8.4.7.Most Prominent KOLs: Analysis by RA score
  • 8.4.8.Most Prominent KOLs: Comparison of RA Score and Third-Party Score

9.COMBINATION THERAPIES

• 9.1.Chapter Overview
• 9.2.Combination Therapies: History of Development
• 9.3.Combination Therapies: FDA Guidelines
  • 9.3.1.Combination of Marketed Drugs
  • 9.3.2.Combinations of Marketed Drugs with New Molecular Entities
  • 9.3.3.Combination of New Molecular Entities
• 9.4.Combination Therapies: Antibody Drug Conjugates
  • 9.4.1.Completed / Ongoing Clinical Studies of Antibody Drug Conjugates
    • 9.4.1.1.Analysis by Type of Therapy
  • 9.4.2.Completed / Ongoing Clinical Studies of Antibody Drug Conjugate-based Combination Therapies
    • 9.4.2.1.Analysis by Phase of Development
    • 9.4.2.2.Analysis by Trial Status
    • 9.4.2.3.Analysis by Target Disease Indication
    • 9.4.2.4.Most Popular Antibody Drug Conjugates Used in Combination Therapies: Analysis by Number of Trials
    • 9.4.2.5.Most Popular Drug Class Used in Combination Therapies: Analysis by Number of Trials
    • 9.4.2.6.Analysis by Target Disease Indication and Drug Class Used in Antibody Drug Conjugate-based Combination Therapies

10. PARTNERSHIPS AND COLLABORATIONS

• 10.1.Chapter Overview
• 10.2.Partnership Models
• 10.3.Antibody Drug Conjugates: List of Partnerships and Collaborations
  • 10.3.1.Analysis by Year of Partnership
  • 10.3.2.Analysis by Type of Partnership
  • 10.3.3.Analysis by Year and Type of Partnership
  • 10.3.4.Analysis by Purpose of Partnership
  • 10.3.5.Analysis by Type of Partner
  • 10.3.6.Most Active Players: Analysis by Number of Partnerships
  • 10.3.7.Analysis by Geography
    • 10.3.7.1.International and Local Agreements
    • 10.3.7.2.Intercontinental and Intracontinental Agreements

11.FUNDING AND INVESTMENT ANALYSIS

• 11.1.Chapter Overview
• 11.2.Types of Funding
• 11.3.Antibody Drug Conjugates: List of Funding and Investment Analysis
  • 11.3.1.Analysis by Year of Funding
  • 11.3.2.Analysis by Amount Invested
  • 11.3.3.Analysis by Type of Funding
  • 11.3.4.Analysis by Year and Type of Funding
  • 11.3.5.Analysis by Type of Investor
  • 11.3.6.Analysis by Amount Invested by Geography
    • 11.3.6.1.Analysis by Region
    • 11.3.6.2.Analysis by Country
  • 11.3.7. Most Active Players: Analysis by Number of Funding Instances
  • 11.3.8. Most Active Players: Analysis by Amount Invested
  • 11.3.9. Key Investors: Analysis by Number of Funding Instances

12.PATENT ANALYSIS

• 12.1.Chapter Overview
• 12.2.Scope and Methodology
• 12.3.Antibody Drug Conjugates: Patent Analysis
  • 12.3.1.Analysis by Patent Publication Year
  • 12.3.2.Analysis by Patent Application Year
  • 12.3.3.Analysis by Annual Number of Granted Patents and Patent Applications
  • 12.3.4.Analysis by Patent Jurisdiction
  • 12.3.5.Analysis by CPC Symbols
  • 12.3.6.Analysis by Type of Applicant
  • 12.3.7.Leading Industry Players: Analysis by Number of Patents
  • 12.3.8.Leading Non-Industry Players: Analysis by Number of Patents
  • 12.3.9.Leading Individual Assignees: Analysis by Number of Patents
• 12.4.Antibody Drug Conjugate: Patent Benchmarking Analysis
  • 12.4.1.Analysis by Patent Characteristics
• 12.5.Antibody Drug Conjugate: Patent Valuation
• 12.6.Leading Patents by Number of Citations

13.ACADEMIC GRANTS ANALYSIS

• 13.1.Chapter Overview
• 13.2.Scope and Methodology
• 13.3.Antibody Drug Conjugates: Grants Analysis
  • 13.3.1.Analysis by Year of Grant Award
  • 13.3.2.Analysis by Amount Awarded
  • 13.3.3.Analysis by Funding Institute
  • 13.3.4.Analysis by Support Period
  • 13.3.5.Analysis by Type of Grant Application
  • 13.3.6.Analysis by Purpose of Grant Award
  • 13.3.7.Analysis by Activity Code
  • 13.3.8.Analysis by Study Section Involved
  • 13.3.9.Popular NIH Departments: Analysis by Number of Grants
    • 13.3.9.1.Prominent Program Officers: Analysis by Number of Grants
    • 13.3.9.2.Popular Recipient Organizations: Analysis by Number of Grants
    • 13.3.9.3.Popular Recipient Organizations: Analysis by Grant Amount
  • 13.3.10. Analysis by Region of Recipient Organization

14.KEY COMMMERCIALIZATION STRATEGIES

• 14.1.Chapter Overview
• 14.2.Successful Drug Launch Strategy: ROOTS Framework
• 14.3.Successful Drug Launch Strategy: Product Differentiation
• 14.4.Common Commercialization Strategies Adopted Across Different Stages of Product Development
• 14.5.Key Commercialization Strategies Adopted by the Companies Focused on Antibody Drug Conjugates
  • 14.5.1.Participation in the Global Events
  • 14.5.2.Collaboration with External Stakeholders and Pharmaceuticals Firms
  • 14.5.3.Geographical Expansion
  • 14.5.4.Awareness Through Product Website
• 14.6.Concluding Remarks

15.PROMOTIONAL ANALYSIS

• 15.1.Chapter Overview
• 15.2.Channels Used for Promotional Campaigns
• 15.3.Summary of Product Website
• 15.4.Summary of Patient Support Services and Informative Downloads
• 15.5.Adcetris: Promotional Analysis
  • 15.5.1.Drug Overview
  • 15.5.2.Product Website Analysis
    • 15.5.2.1.Message for Healthcare Professional
    • 15.5.2.2.Message for Patients
    • 15.5.2.3.Informative Downloads
    • 15.5.2.4.Patient Support Services
• 15.6.Besponsa: Promotional Analysis
  • 15.6.1.Drug Overview
  • 15.6.2.Product Website Analysis
    • 15.6.2.1.Message for Healthcare Professional
    • 15.6.2.2.Message for Patients
    • 15.6.2.3.Informative Downloads
    • 15.6.2.4.Patient Support Services
• 15.7.Enhertu: Promotional Analysis
  • 15.7.1.Drug Overview
  • 15.7.2.Product Website Analysis
    • 15.7.2.1.Message for Healthcare Professional
    • 15.7.2.2.Message for Patients
    • 15.7.2.3.Informative Downloads
    • 15.7.2.4.Patient Support Services
• 15.8.Kadcyla: Promotional Analysis
  • 15.8.1.Drug Overview
  • 15.8.2.Product Website Analysis
    • 15.8.2.1.Message for Healthcare Professional
    • 15.8.2.2.Message for patients
    • 15.8.2.3.Informative Downloads
    • 15.8.2.4.Patient Support Services
• 15.9.Mylotarg: Promotional Analysis
  • 15.9.1.Drug Overview
  • 15.9.2.Product Website Analysis
    • 15.9.2.1.Message for Healthcare Professional
    • 15.9.2.2.Message for patients
    • 15.9.2.3.Informative Downloads
    • 15.9.2.4.Patient Support Services
• 15.10.Polivy: Promotional Analysis
  • 15.10.1.Drug Overview
  • 15.10.2.Product Website Analysis
    • 15.10.2.1.Message for Healthcare Professional
    • 15.10.2.2.Message for Patients
    • 15.10.2.3.Informative Downloads
    • 15.10.2.4.Patient Support Services
• 15.11.Trodelvy: Promotional Analysis
  • 15.11.1.Drug Overview
  • 15.11.2.Product Website Analysis
    • 15.11.2.1.Message for Healthcare Professional
    • 15.11.2.2.Message for Patients
    • 15.11.2.3.Informative Downloads
    • 15.11.2.4.Patient Support Services

16.SUCCESS PROTOCOL ANALYSIS

• 16.1.Chapter Overview
• 16.2.Antibody Drug Conjugates: Success Protocol Analysis
• 16.3.Adcetris (Seagen / Takeda Oncology)
  • 16.3.1.Overview
  • 16.3.2.Approval Timeline
  • 16.3.3.Success Protocol Analysis
• 16.4.Aidixi (RemeGen)
  • 16.4.1.Overview
  • 16.4.2.Approval Timeline
  • 16.4.3.Success Protocol Analysis
• 16.5.Akalux (Rakuten Medical)
  • 16.5.1.Overview
  • 16.5.2.Approval Timeline
  • 16.5.3.Success Protocol Analysis
• 16.6.Besponsa (Pfizer / UCB)
  • 16.6.1.Overview
  • 16.6.2.Approval Timeline
  • 16.6.3.Success Protocol Analysis
• 16.7.Blenrep (GlaxoSmithKline)
  • 16.7.1.Overview
  • 16.7.2.Approval Timeline
  • 16.7.3.Success Protocol Analysis
• 16.8.Elahere (ImmunoGen)
  • 16.8.1.Overview
  • 16.8.2.Approval Timeline
  • 16.8.3.Success Protocol Analysis
• 16.9.Enhertu (Daiichi Sankyo / AstraZeneca)
  • 16.9.1.Overview
  • 16.9.2.Approval Timeline
  • 16.9.3.Success Protocol Analysis
• 16.10.Kadcyla (Genentech / ImmunoGen)
  • 16.10.1.Overview
  • 16.10.2.Approval Timeline
  • 16.10.3.Success Protocol Analysis
• 16.11.Padcev (Seagen / Astellas Pharma)
  • 16.11.1.Overview
  • 16.11.2.Approval Timeline
  • 16.11.3.Success Protocol Analysis
• 16.12.Polivy (Genentech)
  • 16.12.1.Overview
  • 16.12.2. Approval Timeline
  • 16.12.3. Success Protocol Analysis
• 16.13.Tivdak (Seagen / Genmab)
  • 16.13.1.Overview
  • 16.13.2.Approval Timeline
  • 16.13.3.Success Protocol Analysis
• 16.14.Trodelvy (Gilead Sciences)
  • 16.14.1.Overview
  • 16.14.2.Approval Timeline
  • 16.14.3.Success Protocol Analysis
• 16.15. Zynlonta (ADC Therapeutics)
  • 16.15.1.Overview
  • 16.15.2.Approval Timeline
  • 16.15.3.Success Protocol Analysis
• 16.16.Concluding Remarks

17. NOVEL CONJUGATION AND LINKER TECHNOLOGY PLATFORMS

• 17.1.Chapter Overview
• 17.2.Antibody Drug Conjugates: Conjugation Technologies
  • 17.2.1.Chemical Conjugation
  • 17.2.2.Enzymatic Conjugation
• 17.3.Antibody Drug Conjugates: List of Conjugation Technologies
• 17.4.Antibody Drug Conjugates: Linker Technologies
  • 17.4.1.Non-cleavable Linkers
  • 17.4.2.Cleavable Linker
• 17.5.Antibody Drug Conjugates: List of Linker and Linker-Payload Technologies
• 17.6.Concluding Remarks

18.ASSESSMENT OF NON-CLINICAL DATA FIRST IN HUMAN DOSING

• 18.1.Chapter Overview
• 18.2.Antibody Drug Conjugates: Non-Clinical Studies
• 18.3.ICH S9 Guidelines
• 18.4.Investigational New Drug (IND)-Enabling Study Designs
  • 18.4.1.Example Case: Kadcyla
• 18.5.Toxicities in Animal Models
• 18.6.Prediction of Maximum Tolerated Dosage (MTD) in Humans
• 18.7.Other Key Considerations for Study Design

19.COST PRICE ANALYSIS

• 19.1.Chapter Overview
• 19.2.Factors Contributing Towards the High Price of Antibody-Drug Conjugates
• 19.3.Antibody Drug Conjugates Market: Cost Price Analysis
  • 19.3.1.On the Basis of Associated Costs
  • 19.3.2.On the Basis of Competition
  • 19.3.3.On the Basis of Patient Segment
• 19.4.Reimbursement Considerations for Antibody-Drug Conjugates

20.CASE STUDY 1: CONTRACT MANUFACTURING OF ANTIBODY-DRUG CONJUGATES

• 20.1.Chapter Overview
• 20.2.Key Steps in Antibody Drug Conjugate Manufacturing Process
• 20.3.Technical Challenges Related to Antibody Drug Conjugate Manufacturing
• 20.4.Challenges Associated with Supply Chain and Method Transfer
• 20.5.Limitations of In-House Manufacturing
• 20.6.Investments in Antibody Drug Conjugate Manufacturing Capability Expansions
• 20.7.Collaborations Established for Antibody-Drug Conjugate Manufacturing
• 20.8.Growing Demand for Antibody-Drug Conjugate Contract Manufacturing
• 20.9.CMOs with Linker Manufacturing Capabilities
• 20.10.CMOs with HPAPI / Cytotoxic Payload Manufacturing Capabilities
• 20.11.CMOs with Conjugation Capabilities
• 20.12.Antibody Drug Conjugate One-Stop-Shops
• 20.13.Increasing Demand for One-Stop-Shops

21.CASE STUDY 2: COMPANION DIAGNOSTICS FOR ANTIBODY DRUG CONJUGATES THERAPEUTICS

• 21.1.Chapter Overview
  • 21.1.1.Advantages of Companion Diagnostics
  • 21.1.2.Challenges Associated with the Development of Companion Diagnostics
• 21.2. Companion Diagnostics for Antibody Drug Conjugates
• 21.3.Companion Diagnostics For Antibody Therapeutics
  • 21.3.1.Analysis by Target Antigen
  • 21.3.2.Analysis by Type of Cancer
• 21.4.Most Prominent Players: Analysis by Number of Tests

22.SWOT ANALYSIS

• 22.1.Chapter Overview
• 22.2.Strengths
  • 22.2.1.Improved Safety and Patient Adherence
  • 22.2.2.Rise of Next-Generation Conjugation Technologies
  • 22.2.3.Robust Pipeline with Multiple Late Stage Product Candidates
  • 22.2.4.Growing Involvement of Academic Institutes
• 22.3.Weaknesses
  • 22.3.1.Technical Complexities Associated with Product Development
  • 22.3.2.Manufacturing, Logistics and Supply Chain Challenges
  • 22.3.3.Batch to Batch Inconsistencies
• 22.4.Opportunities
  • 22.4.1.Increasing Collaborations and VC Funding
  • 22.4.2.Widening Therapeutics Reach
  • 22.4.3.Life Cycle Management
  • 22.4.4.Combination Therapies
  • 22.4.5.Opportunities for CMOs
• 22.5.Threats
  • 22.5.1.Failure of Clinical / Marketed Candidates
  • 22.5.2.Increased Competition from Other Therapeutic Classes

23. MARKET FORECAST AND OPPORTUNITY ANALYSIS

• 23.1.Chapter Overview
• 23.2.Forecast Methodology and Key Assumptions
• 23.3.Global Antibody Drug Conjugates Market, till 2035
  • 23.3.1.Global Antibody Drug Conjugates Market: Distribution by Target Disease Indication, 2023 and 2035
    • 23.3.1.1.Antibody Drug Conjugates Market for Breast Cancer, till 2035
    • 23.3.1.2.Antibody Drug Conjugates Market for B-cell Lymphoma, till 2035
    • 23.3.1.3.Antibody Drug Conjugates Market for Lung Cancer, till 2035
    • 23.3.1.4.Antibody Drug Conjugates Market for Multiple Myeloma, till 2035
    • 23.3.1.5.Antibody Drug Conjugates Market for Renal Cancer, till 2035
    • 23.3.1.6.Antibody Drug Conjugates Market for Gastric Cancer, till 2035
    • 23.3.1.7.Antibody Drug Conjugates Market for Cervical Cancer, till 2035
    • 23.3.1.8.Antibody Drug Conjugates Market for Acute Lymphoblastic Leukemia, till 2035
    • 23.3.1.9.Antibody Drug Conjugates Market for Other Disease Indications, till 2035
  • 23.3.2.Antibody Drug Conjugates Market: Distribution by Therapeutic Area, Current Year and 2035
    • 23.3.2.1.Antibody Drug Conjugates Market for Solid Tumors, till 2035
    • 23.3.2.2.Antibody Drug Conjugates Market for Hematological Cancer, till 2035
  • 23.3.3.Global Antibody Drug Conjugates Market: Distribution by Linker, 2023 and 2035
    • 23.3.3.1.Antibody Drug Conjugates Market for Valine-Citrulline Linker, till 2035
    • 23.3.3.2.Antibody Drug Conjugates Market for Tetrapeptide-Based Linker, till 2035
    • 23.3.3.3.Antibody Drug Conjugates Market for Succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate Linker, till 2035
    • 23.3.3.4.Antibody Drug Conjugates Market for Maleimide Linker, till 2035
    • 23.3.3.5.Antibody Drug Conjugates Market for Maleimidocaproyl Linker, till 2035
    • 23.3.3.6.Antibody Drug Conjugates Market for Valine-Alanine Linker, till 2035
    • 23.3.3.7.Antibody Drug Conjugates Market for Hydrazone (4-(4-acetylphenoxy) butanoic acid (AcBut) Linker, till 2035
    • 23.3.3.8.Antibody Drug Conjugates Market for Other Linkers, till 2035
  • 23.3.4.Antibody Drug Conjugates Market: Distribution by Type of Payload, Current Year and 2035
    • 23.3.4.1.Antibody Drug Conjugates Market for Monomethyl Auristatin E Payloads, till 2035
    • 23.3.4.2.Antibody Drug Conjugates Market for DM1 Payloads, till 2035
    • 23.3.4.3.Antibody Drug Conjugates Market for SN-38 / Irinotecan Payloads, till 2035
    • 23.3.4.4.Antibody Drug Conjugates Market for Monomethyl Auristatin F Payloads, till 2035
    • 23.3.4.5.Antibody Drug Conjugates Market for Duocarmycin Payloads, till 2035
    • 23.3.4.6.Antibody Drug Conjugates Market for SG3199 Payloads, till 2035
    • 23.3.4.7.Antibody Drug Conjugates Market for Ozogamicin Payloads, till 2035
    • 23.3.4.8.Antibody Drug Conjugates Market for DM4 Payloads, till 2035
    • 23.3.4.9.Antibody Drug Conjugates Market for Other Payloads, till 2035
  • 23.3.5.Global Antibody Drug Conjugates Market: Distribution by Target Antigen, Current Year and 2035
    • 23.3.5.1.Antibody Drug Conjugates Market for HER-2 (ERBB2), till 2035
    • 23.3.5.2.Antibody Drug Conjugates Market for CD79b, till 2035
    • 23.3.5.3.Antibody Drug Conjugates Market for TROP-2, till 2035
    • 23.3.5.4.Antibody Drug Conjugates Market for BCMA (TNFRSF17 / BCM), till 2035
    • 23.3.5.5.Antibody Drug Conjugates Market for CD19, till 2035
    • 23.3.5.6.Antibody Drug Conjugates Market for Nectin 4, till 2035
    • 23.3.5.7.Antibody Drug Conjugates Market for Tissue Factor, till 2035
    • 23.3.5.8.Antibody Drug Conjugates Market for CD22, till 2035
    • 23.3.5.9.Antibody Drug Conjugates Market for CD30, till 2035
    • 23.3.5.10.Antibody Drug Conjugates Market for CEACAM5, till 2035
    • 23.3.5.11.Antibody Drug Conjugates Market for Other Target Antigens, till 2035
  • 23.3.6.Antibody Drug Conjugates Market: Distribution by Geographical Regions, Current Year and 2035
    • 23.3.6.1.Antibody Drug Conjugates Market in North America, till 2035
      • 23.3.6.1.1.Antibody Drug Conjugates Market in US, till 2035
      • 23.3.6.1.2.Antibody Drug Conjugates Market in Canada, till 2035
    • 23.3.6.2.Antibody Drug Conjugates Market in Europe, till 2035
      • 23.3.6.2.1.Antibody Drug Conjugates Market in Germany, till 2035
      • 23.3.6.2.2.Antibody Drug Conjugates Market in UK, till 2035
      • 23.3.6.2.3.Antibody Drug Conjugates Market in France, till 2035
      • 23.3.6.2.4.Antibody Drug Conjugates Market in Italy, till 2035
      • 23.3.6.2.5.Antibody Drug Conjugates Market in Spain, till 2035
    • 23.3.6.3.Antibody Drug Conjugates Market in Asia-Pacific, till 2035
      • 23.3.6.3.1.Antibody Drug Conjugates Market in China, till 2035
      • 23.3.6.3.2.Antibody Drug Conjugates Market in Australia, till 2035
      • 23.3.6.3.3.Antibody Drug Conjugates Market in Japan, till 2035
• 23.4.Antibody Drug Conjugates Market: Product-wise Sales Forecast, till 2035
  • 23.4.1.Adcetris
    • 23.4.1.1.Sales Forecast (USD Billion)
    • 23.4.1.2.Net Present Value (USD Billion)
    • 23.4.1.3.Value Creation Analysis
  • 23.4.2.Aidixi
    • 23.4.2.1.Sales Forecast (USD Billion)
    • 23.4.2.2.Net Present Value (USD Billion)
    • 23.4.2.3.Value Creation Analysis
  • 23.4.3.Besponsa
    • 23.4.3.1.Sales Forecast (USD Billion)
    • 23.4.3.2.Net Present Value (USD Billion)
    • 23.4.3.3.Value Creation Analysis
  • 23.4.4.Blenrep
    • 23.4.4.1.Sales Forecast (USD Billion)
    • 23.4.4.2.Net Present Value (USD Billion)
    • 23.4.4.3.Value Creation Analysis
  • 23.4.5.Elahere
    • 23.4.5.1.Sales Forecast (USD Billion)
    • 23.4.5.2.Net Present Value (USD Billion)
    • 23.4.5.3.Value Creation Analysis
  • 23.4.6.Enhertu
    • 23.4.6.1.Sales Forecast (USD Billion)
    • 23.4.6.2.Net Present Value (USD Billion)
    • 23.4.6.3.Value Creation Analysis
  • 23.4.7.Kadcyla
    • 23.4.7.1.Sales Forecast (USD Billion)
    • 23.4.7.2.Net Present Value (USD Billion)
    • 23.4.7.3.Value Creation Analysis
  • 23.4.8.Padcev
    • 23.4.8.1.Sales Forecast (USD Billion)
    • 23.4.8.2.Net Present Value (USD Billion)
    • 23.4.8.3.Value Creation Analysis
  • 23.4.9.Polivy
    • 23.4.9.1.Sales Forecast (USD Billion)
    • 23.4.9.2.Net Present Value (USD Billion)
    • 23.4.9.3.Value Creation Analysis
  • 23.4.10. Tivdak
    • 23.4.10.1.Sales Forecast (USD Billion)
    • 23.4.10.2.Net Present Value (USD Billion)
    • 23.4.10.3.Value Creation Analysis
  • 23.4.11. Trodelvy
    • 23.4.11.1.Sales Forecast (USD Billion)
    • 23.4.11.2.Net Present Value (USD Billion)
    • 23.4.11.3.Value Creation Analysis
  • 23.4.12. Zynlonta
    • 23.4.12.1.Sales Forecast (USD Billion)
    • 23.4.12.2.Net Present Value (USD Billion)
    • 23.4.12.3.Value Creation Analysis
  • 23.4.13. Datopotamab Deruxtecan
    • 23.4.13.1.Sales Forecast (USD Billion)
    • 23.4.13.2.Net Present Value (USD Billion)
    • 23.4.13.3.Value Creation Analysis
  • 23.4.14. Patritumab Deruxtecan
    • 23.4.14.1.Sales Forecast (USD Billion)
    • 23.4.14.2.Net Present Value (USD Billion)
    • 23.4.14.3.Value Creation Analysis
  • 23.4.15. SHR-A1811
    • 23.4.15.1.Sales Forecast (USD Billion)
    • 23.4.15.2.Net Present Value (USD Billion)
    • 23.4.15.3.Value Creation Analysis
  • 23.4.16. SKB264
    • 23.4.16.1.Sales Forecast (USD Billion)
    • 23.4.16.2.Net Present Value (USD Billion)
    • 23.4.16.3.Value Creation Analysis
  • 23.4.17. TAA013
    • 23.4.17.1.Sales Forecast (USD Billion)
    • 23.4.17.2.Net Present Value (USD Billion)
    • 23.4.17.3.Value Creation Analysis
  • 23.4.18. Telisotuzumab Vedotin
    • 23.4.18.1.Sales Forecast (USD Billion)
    • 23.4.18.2.Net Present Value (USD Billion)
    • 23.4.18.3.Value Creation Analysis
  • 23.4.19. Trastuzumab Duocarmazine
    • 23.4.19.1.Sales Forecast (USD Billion)
    • 23.4.19.2.Net Present Value (USD Billion)
    • 23.4.19.3.Value Creation Analysis
  • 23.4.20. Tusamitamab Ravtansine
    • 23.4.20.1.Sales Forecast (USD Billion)
    • 23.4.20.2.Net Present Value (USD Billion)
    • 23.4.20.3.Value Creation Analysis
  • 23.4.21. Upifitamab Rilsodotin
    • 23.4.21.1.Sales Forecast (USD Billion)
    • 23.4.21.2.Net Present Value (USD Billion)
    • 23.4.21.3.Value Creation Analysis

24.EXECUTIVE INSIGHTS

• 24.1.Chapter Overview
• 24.2.Oxford Biotherapeutics
  • 24.2.1.Company Snapshot
  • 24.2.2.Interview Transcript: Christian Rohlff, Founder and Chief Executive Officer
• 24.3.Angiex
  • 24.3.1.Company Snapshot
  • 24.3.2.Interview Transcript: Paul Jaminet, Founder and Chief Operating Officer
• 24.4.Syndivia
  • 24.4.1.Company Snapshot
  • 24.4.2.Interview Transcript: Sasha Koniev, Co-Founder and Chief Executive Officer
• 24.5.BSP Pharmaceuticals
  • 24.5.1.Company Snapshot
  • 24.5.2.Interview Transcript: Aldo Braca, President and Chief Executive Officer and Giorgio Salciarini, Technical Business Development Senior Manager
• 24.6.PolyTherics (an Abzena company)
  • 24.6.1.Company Snapshot
  • 24.6.2.Interview Transcript: John Burt, Former Chief Executive Officer
• 24.7.CureMeta
  • 24.7.1.Company Snapshot
  • 24.7.2.Interview Transcript: Michael Schopperle, Founder and Chief Executive Officer
• 24.8.CytomX Therapeutics
  • 24.8.1.Company Snapshot
  • 24.8.2.Interview Transcript: Jeff Landau, Chief Business Officer and Head of Strategy
• 24.9.NBE-Therapeutics
  • 24.9.1.Company Snapshot
  • 24.9.2.Interview Transcript: Wouter Verhoeven, Former Chief Business Officer
• 24.10.Cerbios-Pharma
  • 24.10.1. Company Snapshot
  • 24.10.2. Interview Transcript: Denis Angioletti, Chief Commercial Officer
• 24.11.Eisai
  • 24.11.1. Company Snapshot
  • 24.11.2. Interview Transcript: Toshimitsu Uenaka, President and Takashi Owa, Senior Vice President and Chief Scientific Officer
• 24.12.AbTis
  • 24.12.1. Company Snapshot
  • 24.12.2. Interview Transcript: Justin Oh, Chief Business Officer
• 24.13.AmbrX
  • 24.13.1. Company Snapshot
  • 24.13.2. Interview Transcript: Sukumar Sakamuri, Former Vice President and Head of Chemistry
• 24.14.Synaffix
  • 24.14.1. Company Snapshot
  • 24.14.2. Interview Transcript: Anthony DeBoer, Vice President, Business Development
• 24.15.Pierre Fabre
  • 24.15.1. Company Snapshot
  • 24.15.2. Interview Transcript: Christian Bailly, Former Director
• 24.16.Catalent Pharma Solutions
  • 24.16.1. Company Snapshot
  • 24.16.2. Interview Transcript: Jennifer L. Mitcham, Former Director, SMARTag ADCs and Bioconjugates and Stacy McDonald, Former Group Product Manager
• 24.17.Lonza
  • 24.17.1. Company Snapshot
  • 24.17.2. Interview Transcript: Laurent Ducry, Former Head of Bioconjugates Commercial Development
• 24.18.Piramal Healthcare
  • 24.18.1. Company Snapshot
  • 24.18.2. Interview Transcript: Mark Wright, Former Site Head
• 24.19.Ajinomoto Bio-Pharma Services
  • 24.19.1. Company Snapshot
  • 24.19.2. Interview Transcript: Tatsuya Okuzumi, General Manager, Business Development, CDMO Business
• 24.20.Cardiff University
  • 24.20.1. Company Snapshot
  • 24.20.2. Interview Transcript: Alan Burnett, Professor, School of Medicine
• 24.21.Anonymous, Director, Business Development, Leading CMO
• 24.22.Anonymous, Chief Executive Officer, Leading CMO

25.CONCLUSION

26.APPENDIX 1: TABULATED DATA

27.APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

관련자료